Select a medication above to begin.
Rinvoq
upadacitinib
Black Box Warnings .
Serious Infections
incr. risk of serious infection leading to hospitalization or death; pulmonary and extrapulmonary TB, invasive fungal infections, and other opportunistic infections observed; most infections occur in combo w/ immunosuppressants; screen for latent TB infection before and during upadacitinib tx; initiate anti-TB tx before upadacitinib tx; weigh risk/benefit in pts w/ chronic or recurrent infection; monitor closely for infection s/sx during and after tx, incl. TB development in pts w/ negative TB test; D/C upadacitinib if serious infection develops
Mortality
higher rate of mortality, incl. sudden cardiovascular death, observed in RA pts 50 yo and older w/ at least 1 cardiovascular risk factor treated w/ another JAK inhibitor (tofacitinib) vs. TNF blockers in a large, randomized, post-marketing study
Malignancies
lymphoma and other malignancies observed w/ upadacitinib; higher rate of malignancies, excluding non-melanoma skin CA, observed in RA pts treated w/ another JAK inhibitor (tofacitinib) vs. TNF blockers; incr. risk in current or past smokers
Major Adverse Cardiovascular Events
higher rate of major adverse cardiovascular events, incl. cardiovascular death, non-fatal MI, and non-fatal stroke, observed in RA pts 50 yo and older w/ at least 1 cardiovascular risk factor treated w/ another JAK inhibitor (tofacitinib) vs. TNF blockers; incr. risk in current or past smokers; D/C upadacitinib in pts that experienced MI or stroke
Thrombosis
thrombosis, incl. DVT, PE, and arterial thrombosis occurred in pts treated w/ upadacitinib and other JAK inhibitors for inflammatory conditions; many adverse events were serious, sometimes fatal; higher rate of thrombosis observed in RA pts 50 yo and older w/ at least 1 cardiovascular risk factor on another JAK inhibitor (tofacitinib) vs. TNF blockers; avoid upadacitinib in pts w/ thrombosis risk; D/C upadacitinib and promptly evaluate pts w/ thrombosis sx
Adult Dosing .
Dosage forms: ER TAB: 15 mg, 30 mg, 45 mg
Special Note
- [formulation clarification]
- Info: Rinvoq not interchangeable w/ Rinvoq LQ; do not substitute on a mg to mg basis
rheumatoid arthritis, moderate-severe
- [15 mg PO qd]
- Info: see pkg insert for toxicity-related dose adjustments; do not cut/crush/chew tab
psoriatic arthritis
- [15 mg PO qd]
- Info: see pkg insert for toxicity-related dose adjustments; do not cut/crush/chew tab
ankylosing spondylitis
- [15 mg PO qd]
- Info: see pkg insert for toxicity-related dose adjustments; do not cut/crush/chew tab
axial spondyloarthritis, non-radiographic
- [15 mg PO qd]
- Info: see pkg insert for toxicity-related dose adjustments; do not cut/crush/chew tab
atopic dermatitis, moderate-severe refractory
- [<65 yo]
- Start: 15 mg PO qd; Info: may incr. to 30 mg PO qd if inadequate response; see pkg insert for toxicity-related dose adjustments; use lowest effective dose; do not cut/crush/chew tab; D/C if inadequate response w/ dose incr.
- [65 yo and older]
- Dose: 15 mg PO qd; Info: see pkg insert for toxicity-related dose adjustments; do not cut/crush/chew tab
ulcerative colitis, moderate-severe
- [induction tx]
- Dose: 45 mg PO qd x8wk; Info: see pkg insert for toxicity-related dose adjustments; do not cut/crush/chew tab
- [maintenance tx]
- Dose: 15 mg PO qd; Info: may incr. to 30 mg PO qd for refractory, severe, or extensive dz; see pkg insert for toxicity-related dose adjustments; use lowest effective dose; do not cut/crush/chew tab; D/C tx if inadequate response w/ dose incr.
Crohn dz, moderate-severe
- [induction tx]
- Dose: 45 mg PO qd x12wk; Info: see pkg insert for toxicity-related dose adjustments; do not cut/crush/chew tab
- [maintenance tx]
- Dose: 15 mg PO qd; Info: may incr. to 30 mg PO qd for refractory, severe, or extensive dz; see pkg insert for toxicity-related dose adjustments; use lowest effective dose; do not cut/crush/chew tab; D/C tx if inadequate response w/ dose incr.
renal dosing
- [Crohn dz or ulcerative colitis induction tx]
- eGFR 15-30: 30 mg qd; eGFR <15: avoid use
- HD/PD: not defined
- [atopic dermatitis or Crohn dz or ulcerative colitis maintenance tx]
- eGFR 15-30: 15 mg qd; eGFR <15: avoid use
- HD/PD: not defined
- [all other indications]
- eGFR >15: no adjustment; eGFR <15: not defined
- HD/PD: not defined
hepatic dosing
- [Crohn dz or ulcerative colitis induction tx]
- Child-Pugh Class A or B: 30 mg qd; Child-Pugh Class C: avoid use
- [Crohn dz or ulcerative colitis maintenance tx]
- Child-Pugh Class A or B: 15 mg qd; Child-Pugh Class C: avoid use
- [all other indications]
- Child-Pugh Class C: avoid use
Peds Dosing .
- Dosage forms: ER TAB: 15 mg, 30 mg
Special Note
- [formulation clarification]
- Info: Rinvoq not interchangeable w/ Rinvoq LQ; do not substitute on a mg to mg basis
psoriatic arthritis
- [2 yo and older, >30 kg]
- Dose: 15 mg PO qd; Info: see pkg insert for toxicity-related dose adjustments; do not cut/crush/chew tab
atopic dermatitis, moderate-severe refractory
- [12 yo and older, >40 kg]
- Start: 15 mg PO qd; Info: may incr. to 30 mg PO qd if inadequate response; see pkg insert for toxicity-related dose adjustments; use lowest effective dose; do not cut/crush/chew tab; D/C if inadequate response w/ dose incr.
polyarticular juvenile idiopathic arthritis
- [2 yo and older, >30 kg]
- Dose: 15 mg PO qd; Info: see pkg insert for toxicity-related dose adjustments; do not cut/crush/chew tab
renal dosing
- [atopic dermatitis]
- eGFR 15-30: 15 mg qd; eGFR <15: avoid use
- HD/PD: not defined
- [all other indications]
- eGFR >15: no adjustment; eGFR <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class C: avoid use